Not yet recruitingPHASE1, PHASE2NCT07011589

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Studying Dystrophic epidermolysis bullosa

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M. Peter Marinkovich
Principal Investigator
Matt P Marinkovich, MD
Associate Professor of Dermatology
Intervention
Efgartigimod(biological)
Enrollment
18 enrolled
Eligibility
12 years · All sexes
Timeline
2025 – 2026

Study locations (1)

Collaborators

argenx

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07011589 on ClinicalTrials.gov

Other trials for Dystrophic epidermolysis bullosa

Additional recruiting or active studies for the same condition.

See all trials for Dystrophic epidermolysis bullosa →

← Back to all trials